Complement activation in patients with neuromyelitis optica.
The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a...
| Κύριοι συγγραφείς: | , , , , , , , , , |
|---|---|
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
2014
|
| _version_ | 1826293950026088448 |
|---|---|
| author | Nytrova, P Potlukova, E Kemlink, D Woodhall, M Horakova, D Waters, P Havrdova, E Zivorova, D Vincent, A Trendelenburg, M |
| author_facet | Nytrova, P Potlukova, E Kemlink, D Woodhall, M Horakova, D Waters, P Havrdova, E Zivorova, D Vincent, A Trendelenburg, M |
| author_sort | Nytrova, P |
| collection | OXFORD |
| description | The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition. |
| first_indexed | 2024-03-07T03:38:05Z |
| format | Journal article |
| id | oxford-uuid:bcf7b0b8-8f39-411c-9c8c-c1861dcb1997 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:38:05Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:bcf7b0b8-8f39-411c-9c8c-c1861dcb19972022-03-27T05:28:22ZComplement activation in patients with neuromyelitis optica.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bcf7b0b8-8f39-411c-9c8c-c1861dcb1997EnglishSymplectic Elements at Oxford2014Nytrova, PPotlukova, EKemlink, DWoodhall, MHorakova, DWaters, PHavrdova, EZivorova, DVincent, ATrendelenburg, MThe role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition. |
| spellingShingle | Nytrova, P Potlukova, E Kemlink, D Woodhall, M Horakova, D Waters, P Havrdova, E Zivorova, D Vincent, A Trendelenburg, M Complement activation in patients with neuromyelitis optica. |
| title | Complement activation in patients with neuromyelitis optica. |
| title_full | Complement activation in patients with neuromyelitis optica. |
| title_fullStr | Complement activation in patients with neuromyelitis optica. |
| title_full_unstemmed | Complement activation in patients with neuromyelitis optica. |
| title_short | Complement activation in patients with neuromyelitis optica. |
| title_sort | complement activation in patients with neuromyelitis optica |
| work_keys_str_mv | AT nytrovap complementactivationinpatientswithneuromyelitisoptica AT potlukovae complementactivationinpatientswithneuromyelitisoptica AT kemlinkd complementactivationinpatientswithneuromyelitisoptica AT woodhallm complementactivationinpatientswithneuromyelitisoptica AT horakovad complementactivationinpatientswithneuromyelitisoptica AT watersp complementactivationinpatientswithneuromyelitisoptica AT havrdovae complementactivationinpatientswithneuromyelitisoptica AT zivorovad complementactivationinpatientswithneuromyelitisoptica AT vincenta complementactivationinpatientswithneuromyelitisoptica AT trendelenburgm complementactivationinpatientswithneuromyelitisoptica |